MARKET

SRPT

SRPT

Sarepta Therapeutics Inc
NASDAQ
18.54
-0.42
-2.19%
Opening 15:31 09/24 EDT
OPEN
18.76
PREV CLOSE
18.95
HIGH
19.14
LOW
18.05
VOLUME
1.66M
TURNOVER
--
52 WEEK HIGH
25.32
52 WEEK LOW
14.68
MARKET CAP
1.96B
P/E (TTM)
-11.1549
1D
5D
1M
3M
1Y
5Y
1D
Patent Settlement Clears Key Gene Therapy Risk For Sarepta Therapeutics Stock
Simply Wall St · 9h ago
Sarepta Resolves AAVrh74 Gene Therapy Patent Dispute
TipRanks · 23h ago
*Sarepta Therapeutics, Inc.: Regenxbio and UPenn Agreed not to sue Sarepta or Catalent>SRPT
Dow Jones · 23h ago
REGENXBIO Says All Ongoing Patent Litigation Regarding Patents-In-Suit To Be Terminated With Prejudice; Agrees Not To Sue Sarepta Or Affiliates Over Existing Elevidys Or AAVrh74-Based Capsids
Benzinga · 23h ago
*Sarepta Therapeutics, Inc.: To Pay Regenxbio $39M Within Ten Days of the Effective Date of the Settlement Agreement >SRPT
Dow Jones · 23h ago
*Sarepta Therapeutics, Inc.: Entered Settlement Agreement With Regenxbio, UPenn Trustees, and Catalent >SRPT
Dow Jones · 23h ago
*Sarepta Therapeutics, Inc.: Settlement Regards, Among Other Matters, Resolution of Pending Patent Infringement Litigations >SRPT
Dow Jones · 23h ago
Weekly Report: what happened at SRPT last week (0914-0918)?
Weekly Report · 3d ago
More
About SRPT
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS.

Webull offers Sarepta Therapeutics Inc stock information, including NASDAQ: SRPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRPT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SRPT stock methods without spending real money on the virtual paper trading platform.